NasdaqGS - Nasdaq Real Time Price USD

Definium Therapeutics, Inc. (DFTX)

36.33 -1.63 (-4.29%)

At close: October 30 at 4:00:01 PM EDT

36.36 +0.03 (+0.09%)

After hours: October 30 at 7:24:45 PM EDT

Trade DFTX on Coinbase

Chart Range Bar

Advanced Chart

AlphaSpace Chart

Loading chart for DFTX

38m ago Powered by Yahoo Scout

Definium Therapeutics is preparing to report third-quarter 2026 results on November 9, 2026, following positive Phase III results for DT120 in anxiety and depression. The company also issued employee inducement grants, while DFTX is down 4.29% in the current regular sessionas of November 1, 2026.

Previous Close 37.96
Open 37.24
Bid 27.19 x 200
Ask 46.41 x 200
Day's Range 35.87 - 37.90
52 Week Range 10.47 - 49.70
Volume 1,076,100
Avg. Volume 2,154,415
Market Cap (intraday) 4.882B
Beta (5Y Monthly) 2.19
PE Ratio (TTM) --
EPS (TTM) -3.43
Earnings Date Nov 9, 2026
Forward Dividend & Yield -- (0.00%)
1y Target Est 72.56
Zacks Rating Neutral

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.

definiumtx.com

105

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

DFTX

171.32%

S&P 500 (^GSPC)

10.73%

1-Year Return

DFTX

171.32%

S&P 500 (^GSPC)

11.11%

3-Year Return

DFTX

1,308.14%

S&P 500 (^GSPC)

81.91%

5-Year Return

DFTX

3.89%

S&P 500 (^GSPC)

64.59%

Earnings Per Share

gaap GAAP

nongaap Normalized

gaap GAAP

nongaap Normalized

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q2 FY26

Revenue --

Earnings -158.99M

Profit Margin 0.00%

FY25

FY26

-150M

-100M

-50M

0.0%

Analyst Price Targets

55.00

72.56 Average

36.33 Current

91.00 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Latest Rating

Date 10/9/2026

Analyst JP Morgan

Rating Action Initiated

Rating Overweight

Price Action Announces

Price Target 84

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-20.64%
Return on Equity (ttm)

-64.09%
Revenue (ttm)

--
Net Income Avi to Common (ttm)

-353.78M
Diluted EPS (ttm)

-3.43

Balance Sheet and Cash Flow

Total Cash (mrq)

1.08B
Total Debt/Equity (mrq)

3.97%
Levered Free Cash Flow (ttm)

7.61M

CMPS

HELP

AACG

CLOV

MVIS

U.S. markets closed

Definium Therapeutics, Inc. (DFTX)

Trading disclosure

1.85%

-4.55%

66.04%

171.32%

171.32%

-3.89%

976.44%

What's happening with DFTX?

Definium Therapeutics, Inc. Overview Biotechnology / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Latest Rating

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch